Trending Now Biotech

Top trending biotech news 👨🔬👩🔬 EU regulator backs Eisai US-Biogen Alzheimer’s drug The European Union’s drugs regulator on Thursday (November 14, 2024) recommended approval of Eisai and Biogen’s Leqembi for some patients with early Alzheimer’s disease, reversing its initial decision from four months ago. The backing could make it the EU’s first treatment for the brain-wasting condition if this recommendation is accepted by the European Commission... Check out the full story 👉 https://zurl.co/EGIn (The Hindu) #biotech #alzheimers

Biotech article of the day 🧬 Immune Cell Whisperer, a Biosensor Assay, Discerns Which Pathogens Are Sniffed Out On immune cells, Toll-like receptors are capable of detecting infections just like a sniffer dog, using special sensors known as Toll-like receptors, or TLRs for short. But what signals activate TLRs, and what is the relationship between the scale and nature of this activation and the substance being detected? Check out the full story 👉 https://zurl.co/tZaF (Genetic Engineering & Biotechnology News) #biotech

Ten Years After Keytruda’s Seminal Approval, Immuno-oncology Is Poised for the Next Revolution. While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing newer iterations that will take cancer care to the next level. Checkpoint inhibitors have defined the advent of immuno-oncology. One of the leading examples, Merck’s Keytruda, a PD-1 inhibitor, is the top-selling drug in the... Check out the full story 👉 https://zurl.co/uFgg (BioSpace) #biotech

Happy Friday! Today's top biotech news features the 'Effects of Mutations on Protein-Protein Interactions Predicted by New AI Tool' In humans, hundreds of proteins interact in a complex network dubbed the interactome. Those interactions are further complicated when disease-causing mutations are introduced into genes that code for these proteins. Check out the full story 👉 https://zurl.co/wHoG (Genetic Engineering & Biotechnology News) #biotech #mutation

Biotech provides you with today's top trending news 🧬 Novel Group of Bacterial Toxins Take on Fight Against Antibiotic Resistance Antibiotic resistance is a growing concern. According to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur each year. Check out the full article 👉 https://zurl.co/U15b (Genetic Engineering & Biotechnology News) #biotech

Biotech's article of the day features - rADCs Could Take Cancer Treatment ‘Magic Bullet’ to a New Level 💉 Pharmaceutical companies are combining antibodies with radioisotopes in a bid to more precisely deliver radiation to cancers and tumors. Radiation treatments for cancer often come with side effects like fatigue, hair loss, nausea and skin irritation because as the waves traverse through the body, they... Check out the full article 👉 https://zurl.co/Gy1h (BioSpace) #biotech #cancer

Today's top biotech article features - Neurodegeneration could be countered via activation of neural stem cells 🧬 Neural stem cells (NSCs) are important for the development and regeneration of the nervous system... Check out the full article 👉 https://zurl.co/A3Rn (Genetic Engineering & Biotechnology News) #biotech #genetics

Breakthrough Alzheimer's Drug Targets Key 'Hotspots' to Suppress Toxic Tangles. Brains affected by Alzheimer's disease are characterized by damaging clumps and tangles that interfere with neurons – but a new study describes a drug that could potentially suppress half the problem. The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has shown a positive effect in reducing neuron... Check out the full story 👉 https://zurl.co/pTQF (ScienceAlert) #biotech #genetics

Human Stem Cells Repair Retinas in Monkey Models of Macular Holes. Transplanted human stem cells successfully repaired macular holes in monkey models of the disorder. This is according to a new study from researchers at the Center for Biosystems Dynamics Research at RIKEN, Kober City Eye Hospital, and colleagues at other institutions. Their findings are described in a paper published in... Check out the full story 👉 https://zurl.co/Fq4N (Genetic Engineering & Biotechnology News) #biotech #genetics

Biogen, UCB report phase 3 lupus win, justifying risky bet on asset that failed earlier trial. Biogen and UCB plan to move patients in the existing trial into a long-term open-label study and start a second phase 3. Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus (SLE) and outlining plans to start a second pivotal trial... Check out the full story 👉 https://zurl.co/2r7J (Fierce Biotech) #biotech #genetics